Denali Therapeutics Inc (NAS:DNLI)
$ 20.61 -0.71 (-3.33%) Market Cap: 2.97 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 57/100

Denali Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 03:00PM GMT
Release Date Price: $77.74 (+1.45%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan. And we're continuing the 2021 Healthcare Conference this morning with Denali. I'm joined by the company's CEO, Ryan Watts. And before we get started, I just wanted to let you know that you can use the blue Ask a Question button on the webcast to send questions into a portal. And I could ask them to management once we move to Q&A after Ryan's done presenting. So with that out of the way, let me turn it over to you, Ryan.

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Excellent. Thank you, Jess. Good morning. Great to be here with everyone. Very excited to share with you the progress we've made at Denali over the past year and what we see for the future of Denali, it's a very exciting time. Just a reminder that this is a user-advanced slide deck. So I will be highlighting the slide numbers occasionally in the bottom left-hand corner, especially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot